Recent Advances of Vaccine Adjuvants for Infectious Diseases

Overview

Journal Immune Netw

Specialty Allergy & Immunology

Date 2015 Apr 30

PMID 25922593

Citations 176

Authors

Sujin Lee

Minh Trang Nguyen

Affiliations

Soon will be listed here.

Abstract

Vaccines are the most effective and cost-efficient method for preventing diseases caused by infectious pathogens. Despite the great success of vaccines, development of safe and strong vaccines is still required for emerging new pathogens, re-emerging old pathogens, and in order to improve the inadequate protection conferred by existing vaccines. One of the most important strategies for the development of effective new vaccines is the selection and usage of a suitable adjuvant. Immunologic adjuvants are essential for enhancing vaccine potency by improvement of the humoral and/or cell-mediated immune response to vaccine antigens. Thus, formulation of vaccines with appropriate adjuvants is an attractive approach towards eliciting protective and long-lasting immunity in humans. However, only a limited number of adjuvants is licensed for human vaccines due to concerns about safety and toxicity. We summarize current knowledge about the potential benefits of adjuvants, the characteristics of adjuvants and the mechanisms of adjuvants in human vaccines. Adjuvants have diverse modes of action and should be selected for use on the basis of the type of immune response that is desired for a particular vaccine. Better understanding of current adjuvants will help exploring new adjuvant formulations and facilitate rational design of vaccines against infectious diseases.

Citing Articles

Revolutionizing Nanovaccines: A New Era of Immunization.

Saleh M, El-Moghazy A, Elgohary A, Saber W, Helmy Y Vaccines (Basel). 2025; 13(2).

PMID: 40006673 PMC: 11860605. DOI: 10.3390/vaccines13020126.

Designing a multi-epitope vaccine candidate against human rhinovirus C utilizing immunoinformatics approach.

Mamun T, Ali M, Hosen M, Rahman J, Islam M, Akib M Front Immunol. 2025; 15():1364129.

PMID: 39840071 PMC: 11747413. DOI: 10.3389/fimmu.2024.1364129.

C-Phycocyanin and Phycocyanobilin as a Novel Adjuvant in Hepatitis B Vaccine.

Abdali N, Tabaripour R, Javadi S, Nasirikenari M, Birjandi M, Siavashi V Iran J Pharm Res. 2025; 23(1):e147060.

PMID: 39830668 PMC: 11742379. DOI: 10.5812/ijpr-147060.

A Ferritin-Based Eg95 Nanoparticle Vaccine Adjuvanted with pCpG Eliciting Robust Immune Responses Against Cystic Echinococcosis in Mice Model.

Gao X, Zhu X, Liu X, Zhou C, Shang Y, Wu T Int J Nanomedicine. 2025; 20():309-325.

PMID: 39802377 PMC: 11725278. DOI: 10.2147/IJN.S499938.

An immunoinformatics and extensive molecular dynamics study to develop a polyvalent multi-epitope vaccine against cryptococcosis.

Sami M, Rani N, Elahi M, Hossain M, Al Mueid M, Rahim Z PLoS One. 2024; 19(12):e0315105.

PMID: 39739919 PMC: 11687922. DOI: 10.1371/journal.pone.0315105.

References

OHagan D, Ott G, De Gregorio E, Seubert A . The mechanism of action of MF59 - an innately attractive adjuvant formulation. Vaccine. 2012; 30(29):4341-8. DOI: 10.1016/j.vaccine.2011.09.061. View

Turley C, Rupp R, Johnson C, Taylor D, Wolfson J, Tussey L . Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine. 2011; 29(32):5145-52. DOI: 10.1016/j.vaccine.2011.05.041. View

Gasparini R, Schioppa F, Lattanzi M, Barone M, Casula D, Pellegrini M . Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects. Int J Clin Pract. 2009; 64(4):432-8. DOI: 10.1111/j.1742-1241.2009.02309.x. View

Garcia A, De Sanctis J . An overview of adjuvant formulations and delivery systems. APMIS. 2013; 122(4):257-67. DOI: 10.1111/apm.12143. View

Hutchison S, Benson R, Gibson V, Pollock A, Garside P, Brewer J . Antigen depot is not required for alum adjuvanticity. FASEB J. 2011; 26(3):1272-9. PMC: 3289510. DOI: 10.1096/fj.11-184556. View

Cusi M . Applications of influenza virosomes as a delivery system. Hum Vaccin. 2006; 2(1):1-7. DOI: 10.4161/hv.2.1.2494. View

Gustafson G, Rhodes M . Bacterial cell wall products as adjuvants: early interferon gamma as a marker for adjuvants that enhance protective immunity. Res Immunol. 1992; 143(5):483-8; discussion 573-4. DOI: 10.1016/0923-2494(92)80058-s. View

Calabro S, Tortoli M, Baudner B, Pacitto A, Cortese M, OHagan D . Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine. 2011; 29(9):1812-23. DOI: 10.1016/j.vaccine.2010.12.090. View

Medzhitov R . Toll-like receptors and innate immunity. Nat Rev Immunol. 2002; 1(2):135-45. DOI: 10.1038/35100529. View

10.

Coffman R, Sher A, Seder R . Vaccine adjuvants: putting innate immunity to work. Immunity. 2010; 33(4):492-503. PMC: 3420356. DOI: 10.1016/j.immuni.2010.10.002. View

11.

Baxter D . Active and passive immunity, vaccine types, excipients and licensing. Occup Med (Lond). 2007; 57(8):552-6. DOI: 10.1093/occmed/kqm110. View

12.

Podda A . The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine. 2001; 19(17-19):2673-80. DOI: 10.1016/s0264-410x(00)00499-0. View

13.

Reed S, Bertholet S, Coler R, Friede M . New horizons in adjuvants for vaccine development. Trends Immunol. 2008; 30(1):23-32. DOI: 10.1016/j.it.2008.09.006. View

14.

Garcon N, Vaughn D, Didierlaurent A . Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion. Expert Rev Vaccines. 2012; 11(3):349-66. DOI: 10.1586/erv.11.192. View

15.

Garcon N, Wettendorff M, Van Mechelen M . Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile. Expert Opin Biol Ther. 2011; 11(5):667-77. DOI: 10.1517/14712598.2011.573624. View

16.

Garcon N, Chomez P, Van Mechelen M . GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines. 2007; 6(5):723-39. DOI: 10.1586/14760584.6.5.723. View

17.

Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V . Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine. 2011; 29(13):2461-73. DOI: 10.1016/j.vaccine.2011.01.011. View

18.

Fauci A . Infectious diseases: considerations for the 21st century. Clin Infect Dis. 2001; 32(5):675-85. DOI: 10.1086/319235. View

19.

Lindblad E . Aluminium adjuvants--in retrospect and prospect. Vaccine. 2004; 22(27-28):3658-68. DOI: 10.1016/j.vaccine.2004.03.032. View

20.

Awate S, Babiuk L, Mutwiri G . Mechanisms of action of adjuvants. Front Immunol. 2013; 4:114. PMC: 3655441. DOI: 10.3389/fimmu.2013.00114. View